Начало » Лечение » Ръководства » Ръководство за управление на хроничния хепатит В

Статии

RSS и карта на сайта

Разпространи съдържание
повече

Кой е онлайн

В момента има 5 гости онлайн.

Статистика

посетители след 30 март 2009

Ръководство за управление на хроничния хепатит В - Референции

Версия за печат
[1] EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002: Geneva, Switzerland. Consensus statement(short version). J Hepatol 2003;38:533–540.
[2] Ganem D, Prince AM. Hepatitis B virus infection – naturalhistory and clinical consequences. N Engl J Med 2004;350:1118–1129.
[3] Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS.Management of hepatitis B: summary of a clinical researchworkshop. Hepatology 2007;45:1056–1075.
[4] Liaw YF. Prevention and surveillance of hepatitis B virus-relatedhepatocellular carcinoma. Semin Liver Dis 2005;25:40–47.
[5] Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology2007;45:507–539.
[6] Rizzetto M. Viral hepatitis in the third millennium. Res Virol1998;149:251–256.
[7] Rizzetto M, Ciancio A. Chronic HBV-related liver disease. MolAspects Med 2008;29:72–84.
[8] Zarski JP, Marcellin P, Leroy V, Trepo C, Samuel D, Ganne-Carrie N, et al. Characteristics of patients with chronic hepatitisB in France: predominant frequency of HBe antigen negativecases. J Hepatol 2006;45:355–360.
European Association for the Study of the Liver / Journal of Hepatology 50 (2009) 227–242 239[9] Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: naturalhistory and treatment. Semin Liver Dis 2006;26:142–152.
[10] Fattovich G. Natural history and prognosis of hepatitis B. SeminLiver Dis 2003;23:47–58.
[11] Fattovich G, Bortolotti F, Donato F. Natural history of chronichepatitis B: special emphasis on disease progression and prognosticfactors. J Hepatol 2008;48:335–352.
[12] Fattovich G, Olivari N, Pasino M, D’Onofrio M, Martone E,Donato F. Long-term outcome of chronic hepatitis B inCaucasian patients: mortality after 25 years. Gut 2008;57:84–90.
[13] Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellularcarcinoma in cirrhosis: incidence and risk factors. Gastroenterology2004;127:S35–S50.
[14] Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, PhamBN, Ollivier S, et al. Serum hepatitis B virus DNA levels and liverhistology in inactive HBsAg carriers. J Hepatol 2002;36:543–546.
[15] Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617–624.
[16] Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS,Colombo M, et al. Statements from the Taormina expert meetingon occult hepatitis B virus infection. J Hepatol 2008;49:652–657.
[17] Knoll A, Pietrzyk M, Loss M, Goetz WA, Jilg W. Solid-organtransplantation in HBsAg-negative patients with antibodies toHBV core antigen: low risk of HBV reactivation. Transplantation2005;79:1631–1633.
[18] Marcellin P, Giostra E, Martinot-Peignoux M, Loriot MA, JaegleML, Wolf P, et al. Redevelopment of hepatitis-B surface antigenafter renal transplantation. Gastroenterology 1991;100:1432–1434.
[19] Guyatt GH, Cook DJ, Jaeschke R, Pauker SG, Schunemann HJ. Grades of recommendation for antithrombotic agents: AmericanCollege of Chest Physicians Evidence-Based Clinical PracticeGuidelines (8th Edition). Chest 2008;133:123S–131S.
[20] Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE,Liberati A, et al. Going from evidence to recommendations. BrMed J 2008;336:1049–1051.
[21] Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M,Liberati A, et al. Incorporating onsiderations of resourcesuse into grading recommendations. Br Med J 2008;336:1170–1173.
[22] Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y,Schunemann HJ. What is ‘‘quality of vidence” and why is itimportant to clinicians? Br Med J 2008;336:995–998.
[23] Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y,Alonso-Coello P, et al. GRADE: an emerging consensus onrating quality of evidence and strength of recommendations. Br Med J 2008;336:924–926.
[24] Jaeschke R, Guyatt GH, Dellinger P, Schunemann H, Levy MM,Kunz R, et al. Use of GRADE grid to reach decisions on clinicalpractice guidelines when consensus is elusive. Br Med J 2008;337:744.
[25] Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength ofrecommendations for diagnostic tests and strategies. Br Med J2008;336:1106–1110.
[26] Chevaliez S, Bouvier-Alias M, Laperche S, Pawlotsky JM.Performance of the CobasAmpliPrep/Cobas TaqMan real-timePCR assay for hepatitis B virus DNA quantification. J Clin
Microbiol 2008;46:1716–1723.
[27] Thibault V, Pichoud C, Mullen C, Rhoads J, Smith JB, Bitbol A,et al. Characterization of a new sensitive PCR assay forquantification of viral DNA isolated from patients with hepatitisB virus infections. J Clin Microbiol 2007;45:3948–3953.
[28] Stelzl E, Muller Z, Marth E, Kessler HH. Rapid quantificationof hepatitis B virus DNA by automated sample preparation andreal-time PCR. J Clin Microbiol 2004;42:2445–2449.
[29] Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, et al. Virologic monitoring of hepatitis B virus therapy inclinical trials and practice: recommendations for a standardizedapproach.Gastroenterology 2008;134:405–415.
[30] Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, HeathA. An international collaborative study to establish a WorldHealth Organization international standard for hepatitis B virusDNA nucleic acid amplification techniques. Vox Sang 2001;80:63–71.
[31] Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449–1457.
[32] Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, et al. Meta-analyses of FibroTest diagnostic value inchronic liver disease. BMC Gastroenterol 2007;7:40.
[33] Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, deLeґdinghen V, et al. Non-invasive assessment of liver fibrosis bystiffness measurement in patients with chronic hepatitis B. LiverInt; in press.
[34] Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V,Imbert-Bismut F, et al. Prediction of liver histological lesionswith biochemical markers in patients with chronic hepatitis B. JHepatol 2003;39:222–230.
[35] Ogawa E, Furusyo N, Toyoda K, Takeoka H, Otaguro S, Hamada M, et al. Transient elastography for patients with chronic hepatitisB and C virus infection: non-invasive, quantitative assessment ofliver fibrosis. Hepatol Res 2007;37:1002–1010.
[36] Ngo Y, Benhamou Y, Thibault V, Ingiliz P, Munteanu M, Lebray P, et al. An accurate definition of the status of inactivehepatitis B virus carrier by a combination of biomarkers(FibroTest–ActiTest) and viral load. PLoS ONE 2008;3:e2573.
[37] Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advancedliver disease. N Engl J Med 2004;351:1521–1531.
[38] Chang TT, Gish RG, de Man R, Gadano A, Sollano J, ChaoYC, et al. A comparison of entecavir and lamivudine for HbeAgpositivechronic hepatitis B. N Engl J Med 2006;354:1001–1010.
[39] Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or incombination with lamivudine for HBeAg-positive chronic hepatitis
B: a randomised trial. Lancet 2005;365:123–129.
[40] Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI,et al. A one-year trial of lamivudine for chronic hepatitis B. NEngl J Med 1998;339:61–68.
[41] Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronichepatitis B. N Engl J Med 2007;357:2576–2588.
[42] Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S,Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and thecombination for HBeAg-positive chronic hepatitis B. N Engl JMed 2005;352:2682–2695.
[43] Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, ShiffmanML, et al. Adefovir dipivoxil for the treatment of hepatitis B eantigen-positive chronic hepatitis B. N Engl J Med2003;348:808–816.
[44] Heathcote EJ, Gane E, Deman R, Lee S, Flisiak R, Manns MP,et al. A randomized, double-blind, comparison of tenofovir DF(TDF) versus adefovir dipivoxil (ADV) for the treatment ofHBeAG positive chronic hepatitis B (CHB): Study GS-US-174-0103. Hepatology 2007;46:861A.
[45] Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R,et al. Peginterferon alfa-2a alone, lamivudine alone, and the twoin combination in patients with HBeAg-negative chronic hepatitisB. N Engl J Med 2004;351:1206–1217.
[46] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovirdipivoxil for HBeAg-negative chronic hepatitis B for up to 5years. Gastroenterology 2006;131:1743–1751.240 European Association for the Study of the Liver / Journal of Hepatology 50 (2009) 227–242
[47] Marcellin P, Buti M, Krastev Z, Germanidis G, Kaita KD,Kotzev I, et al. A randomized, double-blind, comparison oftenofovir DF (TDF) versus adefovir dipivoxil (ADV) for thetreatment of HBeAG-negative chronic hepatitis B (CHB): StudyGS-US-174-0102. Hepatology 2007;46:290A–291A.
[48] Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H,Goodman Z, et al. Entecavir versus lamivudine for patients withHBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011–1020.
[49] Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M,Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889–896.
[50] Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Lindsay K, Payne J, et al. A randomized,controlled trial of interferonalfa-2b alone and after prednisone withdrawal for thetreatment of chronic hepatitis B. N Engl J Med 1990;323:295–301.
[51] Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS,Heathcote J. Effect of alpha-interferon treatment in patients withhepatitis B e antigen-positive chronic hepatitis B. A metaanalysis.Ann Intern Med 1993;119:312–323.
[52] Zoulim F, Perrillo R. Hepatitis B: reflections on the currentapproach to antiviral therapy. J Hepatol 2008;48 (Suppl. 1):S2–S19.
[53] Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R,Piratvisuth T, et al. Predicting response topeginterferon alpha-2a, lamivudine and the two combined for HBeAg-negativechronic hepatitis B. Gut 2007;56:699–705.
[54] Fried MW, Piratvisuth T, Lau GKK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HbeAgpositive chronic hepatitis B. Hepatology 2008;47:428–434.
[55] Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, SchalmSW, et al. Predictors of HBeAg loss after lamivudine treatmentfor chronic hepatitis B. Hepatology 2002;36:186–194.
[56] Flink HJ, van Zonneveld M, Hansen BE, de Man RA, SchalmSW, Janssen HL. HBV 99-01 Study Group. Treatment with Peginterferonalpha-2b for HBeAg-positive chronic hepatitis B:HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006;101:297–303.
[57] Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatmentpredict the 5-year ideal response. Hepatology 2007;46:1695–1703.
[58] Heathcote J, George J, Gordon S, Bronowicki JP, Sperl J,Williams R, et al. Tenofovir disoproxil fumarate (TDF) for thetreatment of HBeAg-positive chronic hepatitis B: week 72 TDFdata and week 24 adefovir dipivoxil switch data (study 103). JHepatol 2008;48 (Suppl. 2):S32.
[59] Marcellin P, Jacobson I, Habersetzer F, Senturk H, Andreone P, Moyes C, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF
data and week 24 adefovir dipivoxil switch data (study 102). JHepatol 2008;48 (Suppl. 2):S26.
[60] Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847–851.
[61] Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A,Grazi GL, et al. Evolution of hepatitis B virus polymerase genemutations in hepatitis B e antigen-negative patients receivinglamivudine therapy. Hepatology 2000;32:1145–1153.
[62] Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG,Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardizationof nomenclature and assays and recommendations formanagement. Hepatology 2007;46:254–265.
[63] Lampertico P, Vigano M, Manenti E, Iavarone M, Colombo M.Add-on adefovir prevents the emergence of adefovir resistance inlamivudine-resistant patients: A 4-year study. J Hepatol2008;48:S259.
[64] Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B:prevention of drug resistance. Clin Liver Dis 2007;11:869–892.
[65] Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, et al. Peginterferon alpha-2b is safe and effectivein HBeAg-positive chronic hepatitis B patients with advancedfibrosis. Hepatology 2007;46:388–394.
[66] Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81–90.
[67] Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719–727.
[68] Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK,Rolles K, et al. Lamivudine prophylaxis against reinfection inliver transplantation for hepatitis B cirrhosis. Lancet1996;348:1212–1215.
[69] Samuel D. Management of hepatitis B in liver transplantationpatients. Semin Liver Dis 2004;24 (Suppl. 1):55–62.
[70] Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N,Colombo M, et al. Adefovir dipivoxil for wait-listed and postlivertransplantation patients with lamivudine-resistant hepatitisB: final long-term results. Liver Transplant 2007;13:349–360.
[71] Di Martino V, Thevenot T, Colin JF, Boyer N, Martinot MDegos F, et al. Influence of HIV infection on the response tointerferon therapy and the long-term outcome of chronichepatitis B. Gastroenterology 2002;123:1812–1822.
[72] Hoffmann CJ, Thio CL. Clinical implications of HIV andhepatitis B co-infection in Asia and Africa. Lancet Infect Dis2007;7:402–409.
[73] Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural historyof chronic hepatitis B in co-infected patients. J Hepatol2006;44:S65–S70.
[74] Rockstroh JK. Influence of viral hepatitis on HIV infection. JHepatol 2006;44:S25–S27.
[75] Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A,Rockstroh J, et al. Care of patients with chronic hepatitis Band HIV co-infection: recommendations from an HIV–HBVInternational Panel. AIDS 2005;19:221–240.
[76] Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol2008;48:353–367.
[77] Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, PaluG, et al. Short statement of the first European ConsensusConference on the treatment of chronic hepatitis B and C in HIV
co-infected patients. J Hepatol 2005;42:615–624.
[78] Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S,Peters L, et al. European AIDS Clinical Society (EACS)guidelines for the clinical management and treatment of chronichepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9:82–88.
[79] Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, et al. Anti-hepatitis B virus efficacy of tenofovirdisoproxil fumarate in HIV-infected patients. Hepatology2006;43:548–555.
[80] Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, et al. Efficacy of peginterferon alpha-2b inchronic hepatitis delta: relevance of quantitative RT-PCR forfollow-up. Hepatology 2006;44:728–735.
[81] Farci P. Treatment of chronic hepatitis D: new advances, oldchallenges. Hepatology 2006;44:536–539.
European Association for the Study of the Liver / Journal of Hepatology 50 (2009) 227–242 241
[82] Farci P, Chessa L, Balestrieri C, Serra G, Lai ME. Treatment ofchronic hepatitis D. J Viral Hepat 2007;14:58–63.
[83] Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van EP, et al.Treatment of chronic hepatitis D with interferon alfa-2a. N EnglJ Med 1994;330:88–94.
[84] Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, OliveroA, et al. Pegylated interferon alpha-2b as monotherapy or incombination with ribavirin in chronic hepatitis delta. Hepatology2006;44:713–720.
[85] Wedemeyer H, Yurdaydin C, Dalekos G, Erhardt A, Cakaloglu Y, Degertekin H, et al. 72 week data of the HIDIT-1 trial: a multicenter randomised study comparing peginterferon alpha-2a plus adefovir vs peginterferon alpha-2a plus placebo vs adefovir in chronic delta hepatitis. J Hepatol 2007;46 (Suppl. 1):S4.
[86] Yurdaydin C, Bozkaya H, Karaaslan H, Onder FO, Erkan OE, Yalcin K, et al. A pilot study of 2 years of interferon treatment inpatients with chronic delta hepatitis. J Viral Hepat 2007;14:812–816.
[87] Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, et al. The HEP-NET B/C co-infection trial: aprospective multicenter study to investigate the efficacy ofpegylated interferon-alpha2b and ribavirin in patients withHBV/HCV co-infection. J Hepatol 2008;48:S320.
[88] Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection:epidemiology, clinical features, viral interactions and treatment.J Gastroenterol Hepatol 2008;23:512–520.
[89] Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS.Ribavirin and interferon is effective for hepatitis C virusclearance in hepatitis B and C dually infected patients. Hepatology2003;37:568–576.
[90] Senturk H, Tahan V, Canbakan B, Uraz S, Ulger Y, Ozaras R,et al. Chronic hepatitis C responds poorly to combinationtherapy in chronic hepatitis B carriers. Neth J Med2008;66:191–195.
[91] Zhou J, Dore GJ, Zhang F, Lim PL, Chen YMA. HepatitisB and C virus coinfection in the TREAT Asia HIV
observational database. J Gastroenterol Hepatol 2007;22:1510–1518.
[92] Lee WM, Squires RH, Nyberg SL, Doo E, Hoofnagle JH. Acuteliver failure: summary of a workshop. Hepatology 2008;47:1401–1415.
[93] Roussos A, Koilakou S, Kalafatas C, Kalantzis C, Apostolou N, Grivas E, et al. Lamivudine treatment for acute severe hepatitisB: report of a case and review of the literature. Acta Gastroenterol Belg 2008;71:30–32.
[94] Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et al. Safety and efficacy of lamivudine in patientswith severe acute or fulminant hepatitis B, a multicenterexperience. J Viral Hepat 2006;13:256–263.
[95] Jonas MM, Kelly D, Pollack H, Mizerski J, Sorbel J, FrederickD, et al. Safety, efficacy, and pharmacokinetics of adefovirdipivoxil in children and adolescents (age 2 to <18 years) withchronic hepatitis B. Hepatology 2008;47:1863–1871.
[96] Jonas MM, Little NR, Gardner SD. Long-term lamivudinetreatment of children with chronic hepatitis B: durability oftherapeutic responses and safety. J Viral Hepat 2008;15:20–27.
[97] Pawlowska M, Halota W. Virological response during treatmentof chronic hepatitis B with pegylated interferon alfa-2a inchildren. Gastroenterology 2008;134:A811.
[98] Sokal EM, Kelly D, Wirth S, Mizerski J, Dhawan A, FrederickD. The pharmacokinetics and safety of adefovir dipivoxil inchildren and adolescents with chronic hepatitis B virus infection.J Clin Pharmacol 2008;48:512–517.
[99] Gunson RN, Shouval D, Roggendorf M, Zaaijer H, Nicholas H,Holzmann H, et al. Hepatitis B virus (HBV) and hepatitis C virus(HCV) infections in health care workers (HCWs): guidelines forprevention oftransmission of HBV and HCV from HCW topatients. J Clin Virol 2003;27:213–230.
[100] Terrault NA, Jacobson IM. Treating chronic hepatitis Binfection in patients who are pregnant or are undergoingimmunosuppressive chemotherapy. Semin Liver Dis 2007;27(Suppl. 1):18–24.
[101] van Zonneveld M, van Nunen AB, Niesters HG, de Man RA,Schalm SW, Janssen HL. Lamivudine treatment during pregnancyto prevent perinatal transmission of hepatitis B virusinfection. J Viral Hepat 2003;10:294–297.
[102] ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbationof chronic hepatitis B infection after delivery. J Viral Hepat 2008;15:37–41.
[103] Hui CK, Cheung WWW, Zhang HY, Au WY, Yueng YH, Leung AYH, et al. Rituximab increases the risk of de novohepatitis B infection in hepatitis B surface antigen negativepatients undergoing cytotoxic hemotherapy. J GastroenterolHepatol 2006;21:A73–A74.
[104] Lalazar G, Rund D, Shouval D. Screening, prevention andtreatment of viral hepatitis B reactivation in patients withhaematological malignancies. Br J Hematol 2007;136:699–712.
[105] Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivationafter cytotoxic chemotherapy: the disease and its prevention.Clin Gastroenterol Hepatol 2006;4:1076–1081.
[106] Hsu C, Hsiung CA, Su LJ, Hwang WS, Wang MC, Lin SF, et al.A revisit of prophylactic lamivudine for chemotherapy-associatedhepatitis B reactivation in non-Hodgkin’s lymphoma: arandomized trial. Hepatology 2008;47:844–853.
[107] Hui CK, Liang R, Lau GK. Kinetics of hepatitis B virusreactivation after chemotherapy: more questions than answers.Gastroenterology 2006;131:1656–1657.
[108] Lau GKK. Hepatitis B reactivation after chemotherapy: twodecades of clinical research. Hepatol Int 2008;2:152–162.
[109] Rostaing L, Henry S, Cisterne JM, Duffaut M, Icart J, DurandD. Efficacy and safety of lamivudine on replication of recurrenthepatitis B after cadaveric renal transplantation. Transplantation1997;64:1624–1627.
242 European Association for the Study of the Liver / Journal of Hepatology 50 (2009) 227–242